Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2024.132060 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benefit of coronary stenting using available intracoronary tools in high-risk patients. The OPTI-XIENCE study.
Int J Cardiol
September 2025
Regional University Hospital Jean Minjoz, Besancon, France.
Background: The clinical benefit of using ICT for coronary stent optimization remains uncertain in randomized trials, in which a unique ICT was used in most cases.
Aim: To assess the clinical impact of intracoronary techniques (ICT) for stent optimization in high-risk patients.
Methods: The OPTI-XIENCE study is a prospective, observational, multicenter international study including high-risk patients undergoing coronary stenting, in whom any ICT was used for stent optimization at the operator's discretion.
Complete revascularization with percutaneous coronary intervention for acute coronary syndromes presenting with multivessel disease.
Curr Opin Cardiol
August 2025
Division of Cardiology, University of California, San Francisco, San Francisco, California, USA.
Purpose Of Review: Complete revascularization (CR) by percutaneous coronary intervention (PCI) in acute coronary syndromes with multivessel coronary artery disease (CAD) was previously contraindicated in the absence of cardiogenic shock or high-risk ischemia. Over the last decade, CR has been a focus of recent clinical investigation and practice evolution due to high-quality evidence supporting hard cardiovascular outcome benefit, contributing to a reversal in international guidelines. This review provides concise syntheses of contemporary and emerging randomized evidence underpinning current strategies and unresolved questions regarding patient selection, timing of CR and guidance modalities for the identification and treatment of nonculprit lesions.
View Article and Find Full Text PDFChest pain patterns and coronary microvascular function in non-obstructive coronary artery disease.
EuroIntervention
September 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Background: Coronary microvascular dysfunction (CMD) is a common cause of chest pain (CP) in patients with angina and non-obstructive coronary arteries (ANOCA). Although both CMD and CP have distinct classifications, the relationship between them remains insufficiently understood.
Aims: This study investigated the relationship between CMD and CP patterns and their prognostic impact in ANOCA patients.
Sex Differences in State-of-the-Art Management for Left Main Disease.
JACC Adv
August 2025
National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Background: Although higher mortality has been reported among women undergoing coronary revascularization for left main coronary artery disease (LMD), it remains unclear whether contemporary approaches can address these disparities.
Objectives: We investigated sex differences in outcomes using the DEFINE-LM (deferral of coronary revascularization based on instantaneous wave-free ratio evaluation for left main coronary artery disease) registry, in which state-of-the-art management was employed.
Methods: We analyzed 314 patients from an international, multicenter registry, where all patients received state-of-the-art management, including physiology-guided revascularization decisions, intracoronary imaging-optimized drug-eluting stent deployment, or surgical procedures with internal thoracic artery grafts, alongside guideline-directed medical therapy.
Impact of evolocumab on coronary physiology and microstructure in de-novo heart transplant recipients.
J Heart Lung Transplant
August 2025
Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Background: Cardiac allograft vasculopathy, characterized by arterial intima thickening and microvascular dysfunction, compromises survival after heart transplantation. We investigated the impact of evolocumab on invasive coronary physiology and microstructure after de-novo transplantation.
Methods: In the EVOLVD trial (NCT03734211), the effect of 12 months of evolocumab vs placebo on maximal coronary intimal thickness was assessed using intracoronary ultrasound.